Key Points
- Edwards Lifesciences VP Donald Bobo, Jr. sold 23,145 shares on May 27 at an average price of $86.42, totaling about $2.0 million. After the sale, he still held 98,611 shares, a 19.01% reduction in his position.
- The company recently beat earnings expectations, reporting Q1 EPS of $0.78 versus the $0.73 consensus and revenue of $1.65 billion versus $1.60 billion expected. Revenue rose 16.7% year over year, and Edwards Lifesciences also issued FY 2026 guidance of $2.95 to $3.05 EPS.
- Analyst sentiment remains constructive, with several firms raising price targets, including Barclays at $110 and BTIG and Piper Sandler at $100. The stock currently has a consensus rating of Moderate Buy and an average price target of $95.65.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $86.55 on Thursday. The business has a 50 day simple moving average of $81.62 and a two-hundred day simple moving average of $82.97. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $88.28. The stock has a market capitalization of $49.83 billion, a P/E ratio of 46.04, a PEG ratio of 2.19 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 earnings per share. The business's revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. BTIG Research increased their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the company a "buy" rating in a report on Friday, April 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an "outperform" rating in a report on Monday, April 13th. Wolfe Research raised Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Finally, Barclays reaffirmed an "overweight" rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.65.
Get Our Latest Stock Analysis on Edwards Lifesciences
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. State Street Corp grew its position in Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the period. Wellington Management Group LLP grew its position in Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock worth $1,857,934,000 after acquiring an additional 989,533 shares during the period. Bank of New York Mellon Corp grew its position in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Finally, Norges Bank purchased a new position in Edwards Lifesciences in the fourth quarter worth approximately $803,686,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
